Vectura, the Chippenham-based specialist pharmaceutical firm, has shaken up its boardroom following its £440m merger with Skyepharma in March.
As announced at the time of the tie-up with London-based Skyepharma, Vectura’s chief financial officer Andrew Oakley has stepped down from the board. Andrew joined Vectura in January last year from Swiss biopharma firm Actelion Pharmaceuticals, where he was also CFO.
He is replaced on the Vectura board by Skyepharma CFO Andrew Derodra. Also joining the board are Skyepharma chairman Frank Condella, who becomes vice chairman of the enlarged group, and Thomas Werner, a Skyepharma non-executive director, who takes up a similar role on the new board.
Vectura chairman Bruno Angelici thanked Andrew Oakley for his service to the business.
The merger of Vectura, which is pioneering new ways of treating asthma and lung diseases, with Skyepharma has created a £1bn company generating sales of more than £150m a year.
